All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Markman Underscores Unanswered Questions in Ovarian Cancer Management

November 9th 2023

Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.

PDS0101-Based Triplet Provides Survival Benefit in HPV16+ Cancers

November 9th 2023

The combination of PDS0101, PDS0301 (formerly M-9241), and bintrafusp alfa, an investigational immune checkpoint inhibitor extended survival in patients with advanced human papillomavirus 16–positive cancers, according to final data from a phase 2 trial (NCT04287868) led by the National Cancer Institute.

Durvalumab Plus TACE and Bevacizumab Significantly Improves PFS in Select HCC

November 9th 2023

Durvalumab plus concurrent transarterial chemoembolization followed by durvalumab with bevacizumab resulted in a significant improvement in PFS over TACE alone in patients with hepatocellular carcinoma who are eligible for embolization, meeting the primary end point of the phase 3 EMERALD-1 trial.

FDA Grants Priority Review to Liso-Cel for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

November 9th 2023

The FDA has granted priority review to the supplemental biologics license application seeking approval to expand the indication of lisocabtagene maraleucel to include patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a BTK inhibitor and a BCL-2 inhibitor.

Advanced Bladder Cancer Patients Could Keep Their Bladder Under New Treatment Regime, Clinical Trial Shows

November 9th 2023

Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a recently published study.

FDA Restricts Approval for Pembrolizumab Plus Trastuzumab and Chemo to Advanced PD-L1+ Gastric/GEJ Cancer

November 9th 2023

The FDA has updated the current indication for pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma to those whose tumors express PD-L1 with a CPS of 1 or more.

Prevalence of Eye Toxicities in Patients With Cancer Is Much Higher Than Previously Known

November 9th 2023

In the real-world setting, cases of ocular adverse effects have emerged with greater frequency both in new and established therapies than has been previously observed in many clinical trials.

Recent Clinical Trial Updates Shift DLBCL Treatment Paradigm

November 9th 2023

Gilles Salles, MD, PhD, expands on how data from recent clinical trials have helped shift the treatment paradigm for patients with diffuse large B-cell lymphoma.

Lamanna Details Evolution of CLL Treatment Following Resistance

November 9th 2023

Nicole Lamanna, MD, discusses treatment options for patients with chronic lymphocytic leukemia who develop resistance to a prior treatment.

FDA Approves Fruquintinib for Metastatic Colorectal Cancer

November 8th 2023

The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

FDA Approves Fruquintinib for Metastatic Colorectal Cancer-Audio Test

November 8th 2023

Data Continue to Refine Frontline BTK Inhibitor Selection in CLL

November 8th 2023

Along with the combination of venetoclax and obinutuzumab, the BTK inhibitor–based regimens of zanubrutinib monotherapy and acalabrutinib plus obinutuzumab represent the preferred options in the National Comprehensive Cancer Network Guidelines for the first-line treatment of patients with chronic lymphocytic leukemia without 17p deletions or TP53 mutations.

BXCL701/Pembrolizumab Combo Prolongs OS in mCRPC of Adenocarcinoma Phenotype

November 8th 2023

Treatment with the oral innate immune activator BXCL701 combined with pembrolizumab demonstrated prolonged overall survival in patients with metastatic castration-resistant prostate cancer of adenocarcinoma phenotype.

Frontline Pyrotinib Plus Trastuzumab and Docetaxel Improves PFS in HER2+ Metastatic Breast Cancer

November 8th 2023

The addition of pyrotinib to trastuzumab and docetaxel led to a significant improvement in progression-free survival compared with placebo plus trastuzumab and docetaxel in patients with newly diagnosed, HER2-positive metastatic breast cancer.

Certain Per- and Polyfluoroalkyl “Forever Chemicals” Identified as Potential Risk Factor for Thyroid Cancer

November 8th 2023

Mount Sinai study is first to document association that had been hypothesized.

STEAP1 Offers Potential Multifunctional Target in Prostate Cancer

November 8th 2023

Because STEAP1 is often overexpressed in prostate cancer, a disease that still largely lacks safe and effective treatment options, investigators are using it as the basis for developing novel therapies.

Neoadjuvant Inetetamab Combo Shows Efficacy, Tolerability in Locally Advanced HER2+ Breast Cancer

November 8th 2023

The combination of inetetamab, pertuzumab, paclitaxel, and carboplatin elicited responses with an acceptable safety profile when administered as neoadjuvant treatment in patients with locally advanced HER2-positive breast cancer.

CMG901 Elicits Responses in CLDN18.2-Expressing Gastric/GEJ Cancer

November 7th 2023

CMG901 induced responses with a manageable toxicity profile in patients with CLDN18.2-positive gastric or gastroesophageal junction cancer, according to updated data from the dose-expansion phase of the phase 1 KYM901 study.

Domvanalimab Plus Zimberelimab and Chemotherapy Elicits Responses in Advanced Gastric/GEJ Adenocarcinoma

November 7th 2023

The combination of domvanalimab, zimberelimab, and FOLFOX elicited responses in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, irrespective of PD-L1 status.

Research Remains Focused on Bringing CAR T-Cell Therapy to Solid Tumors

November 7th 2023

Mark Leick, MD, discusses how the emergence of CAR T-cell therapies have affected the treatment paradigms in various hematologic malignancies, expands on how persisting challenges with the use of this type of treatment are being addressed, and details research into the use of CAR T-cell therapy in patients with solid tumors.